LONDON - British technology company Oxford Nanopore said it hoped to reach break-even by the end of 2026, as it outlined plans to drive further growth in the life science research tools market and expand into new areas of healthcare.
As part of its future growth plan, it announced on Thursday a partnership with the U.S. healthcare group Mayo Clinic to develop new clinical tests for diseases, including detection of genetic predisposition to cancer, plus other tests to improve patient care.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: